vs
BELLRING BRANDS, INC.（BRBR）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是BELLRING BRANDS, INC.的1.4倍（$772.1M vs $537.3M），Revvity净利率更高（12.7% vs 8.1%，领先4.6%），Revvity同比增速更快（5.9% vs 0.8%），Revvity自由现金流更多（$161.8M vs $-7.3M），过去两年Revvity的营收复合增速更高（9.0% vs 4.2%）
Bellring Brands是一家知名营养食品企业，研发、生产及销售蛋白饮料、蛋白棒、蛋白粉等功能性营养产品，旗下拥有Premier Protein、Dymatize等知名品牌，主要面向北美市场的健康及运动爱好者，通过零售、电商等多渠道发售。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
BRBR vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.4倍
$537.3M
营收增速更快
RVTY
高出5.0%
0.8%
净利率更高
RVTY
高出4.6%
8.1%
自由现金流更多
RVTY
多$169.1M
$-7.3M
两年增速更快
RVTY
近两年复合增速
4.2%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $537.3M | $772.1M |
| 净利润 | $43.7M | $98.4M |
| 毛利率 | 29.9% | — |
| 营业利润率 | 14.6% | 14.5% |
| 净利率 | 8.1% | 12.7% |
| 营收同比 | 0.8% | 5.9% |
| 净利润同比 | -43.2% | 3.9% |
| 每股收益（稀释后） | $0.36 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BRBRRVTY
| Q4 25 | $537.3M | $772.1M | ||
| Q3 25 | $648.2M | $698.9M | ||
| Q2 25 | $547.5M | $720.3M | ||
| Q1 25 | $588.0M | $664.8M | ||
| Q4 24 | $532.9M | $729.4M | ||
| Q3 24 | $555.8M | $684.0M | ||
| Q2 24 | $515.4M | $691.7M | ||
| Q1 24 | $494.6M | $649.9M |
净利润BRBRRVTY
| Q4 25 | $43.7M | $98.4M | ||
| Q3 25 | $59.6M | $46.7M | ||
| Q2 25 | $21.0M | $53.9M | ||
| Q1 25 | $58.7M | $42.2M | ||
| Q4 24 | $76.9M | $94.6M | ||
| Q3 24 | $71.7M | $94.4M | ||
| Q2 24 | $73.7M | $55.4M | ||
| Q1 24 | $57.2M | $26.0M |
毛利率BRBRRVTY
| Q4 25 | 29.9% | — | ||
| Q3 25 | 28.9% | 53.6% | ||
| Q2 25 | 35.4% | 54.5% | ||
| Q1 25 | 32.3% | 56.5% | ||
| Q4 24 | 37.5% | — | ||
| Q3 24 | 36.9% | 56.3% | ||
| Q2 24 | 36.8% | 55.7% | ||
| Q1 24 | 33.2% | 54.6% |
营业利润率BRBRRVTY
| Q4 25 | 14.6% | 14.5% | ||
| Q3 25 | 15.8% | 11.7% | ||
| Q2 25 | 8.2% | 12.6% | ||
| Q1 25 | 16.2% | 10.9% | ||
| Q4 24 | 21.6% | 16.3% | ||
| Q3 24 | 20.2% | 14.3% | ||
| Q2 24 | 21.7% | 12.4% | ||
| Q1 24 | 18.4% | 6.8% |
净利率BRBRRVTY
| Q4 25 | 8.1% | 12.7% | ||
| Q3 25 | 9.2% | 6.7% | ||
| Q2 25 | 3.8% | 7.5% | ||
| Q1 25 | 10.0% | 6.4% | ||
| Q4 24 | 14.4% | 13.0% | ||
| Q3 24 | 12.9% | 13.8% | ||
| Q2 24 | 14.3% | 8.0% | ||
| Q1 24 | 11.6% | 4.0% |
每股收益（稀释后）BRBRRVTY
| Q4 25 | $0.36 | $0.86 | ||
| Q3 25 | $0.48 | $0.40 | ||
| Q2 25 | $0.16 | $0.46 | ||
| Q1 25 | $0.45 | $0.35 | ||
| Q4 24 | $0.59 | $0.77 | ||
| Q3 24 | $0.54 | $0.77 | ||
| Q2 24 | $0.56 | $0.45 | ||
| Q1 24 | $0.43 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $64.1M | $919.9M |
| 总债务越低越好 | $1.2B | — |
| 股东权益账面价值 | $-510.7M | $7.3B |
| 总资产 | $1.1B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BRBRRVTY
| Q4 25 | $64.1M | $919.9M | ||
| Q3 25 | $71.8M | $931.4M | ||
| Q2 25 | $43.7M | $991.8M | ||
| Q1 25 | $28.1M | $1.1B | ||
| Q4 24 | $49.6M | $1.2B | ||
| Q3 24 | $70.8M | $1.2B | ||
| Q2 24 | $72.6M | $2.0B | ||
| Q1 24 | $79.3M | $1.7B |
总债务BRBRRVTY
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.0B | — | ||
| Q1 25 | $953.7M | — | ||
| Q4 24 | $833.4M | — | ||
| Q3 24 | $833.1M | — | ||
| Q2 24 | $832.7M | — | ||
| Q1 24 | $832.4M | — |
股东权益BRBRRVTY
| Q4 25 | $-510.7M | $7.3B | ||
| Q3 25 | $-453.9M | $7.4B | ||
| Q2 25 | $-309.9M | $7.6B | ||
| Q1 25 | $-254.1M | $7.6B | ||
| Q4 24 | $-146.6M | $7.7B | ||
| Q3 24 | $-205.9M | $7.9B | ||
| Q2 24 | $-243.2M | $7.9B | ||
| Q1 24 | $-247.7M | $7.8B |
总资产BRBRRVTY
| Q4 25 | $1.1B | $12.2B | ||
| Q3 25 | $941.0M | $12.1B | ||
| Q2 25 | $993.7M | $12.4B | ||
| Q1 25 | $947.5M | $12.4B | ||
| Q4 24 | $885.2M | $12.4B | ||
| Q3 24 | $837.0M | $12.8B | ||
| Q2 24 | $804.1M | $13.4B | ||
| Q1 24 | $765.0M | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-3.1M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $-7.3M | $161.8M |
| 自由现金流率自由现金流/营收 | -1.4% | 21.0% |
| 资本支出强度资本支出/营收 | 0.8% | 2.6% |
| 现金转化率经营现金流/净利润 | -0.07× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $246.9M | $509.4M |
8季度趋势，按日历期对齐
经营现金流BRBRRVTY
| Q4 25 | $-3.1M | $182.0M | ||
| Q3 25 | $169.1M | $138.5M | ||
| Q2 25 | $40.3M | $134.3M | ||
| Q1 25 | $48.2M | $128.2M | ||
| Q4 24 | $3.0M | $174.2M | ||
| Q3 24 | $40.1M | $147.9M | ||
| Q2 24 | $69.0M | $158.6M | ||
| Q1 24 | $16.3M | $147.6M |
自由现金流BRBRRVTY
| Q4 25 | $-7.3M | $161.8M | ||
| Q3 25 | $168.1M | $120.0M | ||
| Q2 25 | $38.5M | $115.5M | ||
| Q1 25 | $47.6M | $112.2M | ||
| Q4 24 | $1.7M | $149.8M | ||
| Q3 24 | $38.9M | $125.6M | ||
| Q2 24 | $68.9M | $136.6M | ||
| Q1 24 | $16.0M | $129.7M |
自由现金流率BRBRRVTY
| Q4 25 | -1.4% | 21.0% | ||
| Q3 25 | 25.9% | 17.2% | ||
| Q2 25 | 7.0% | 16.0% | ||
| Q1 25 | 8.1% | 16.9% | ||
| Q4 24 | 0.3% | 20.5% | ||
| Q3 24 | 7.0% | 18.4% | ||
| Q2 24 | 13.4% | 19.7% | ||
| Q1 24 | 3.2% | 20.0% |
资本支出强度BRBRRVTY
| Q4 25 | 0.8% | 2.6% | ||
| Q3 25 | 0.2% | 2.6% | ||
| Q2 25 | 0.3% | 2.6% | ||
| Q1 25 | 0.1% | 2.4% | ||
| Q4 24 | 0.2% | 3.4% | ||
| Q3 24 | 0.2% | 3.3% | ||
| Q2 24 | 0.0% | 3.2% | ||
| Q1 24 | 0.1% | 2.7% |
现金转化率BRBRRVTY
| Q4 25 | -0.07× | 1.85× | ||
| Q3 25 | 2.84× | 2.97× | ||
| Q2 25 | 1.92× | 2.49× | ||
| Q1 25 | 0.82× | 3.03× | ||
| Q4 24 | 0.04× | 1.84× | ||
| Q3 24 | 0.56× | 1.57× | ||
| Q2 24 | 0.94× | 2.87× | ||
| Q1 24 | 0.28× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BRBR
| Shakesandotherbeverages | $432.4M | 80% |
| Powders | $92.1M | 17% |
| Other Products | $12.8M | 2% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
